Health

Discover how FluCamp pioneers clinical trials, bridging lab discoveries and revolutionary treatments, ensuring safety and efficacy in modern medicine...
Cizzle Biotechnology Holdings plc has launched a new corporate website, enhancing access to vital information about its early cancer tests and growth strategy...
Professor Sir Chris Evans, Founder and Chief Scientific Officer of EDX Medical, explains how this revolutionary blood test could reshape early diagnosis and monitoring..
Convatec Group Plc celebrates the CMS's postponement of LCDs for diabetic foot ulcers, ensuring continued access to their trusted InnovaMatrix® for Medicare patients...
Poolbeg Pharma is innovating in oncology with POLB 001, a promising p38 MAP kinase inhibitor targeting Cytokine Release Syndrome, a critical complication in cancer therapies...
One Health Group is set to transform orthopaedic care in the North of England with its first surgical hub, enhancing patient access to essential NHS services...
EDX Medical Group is set to launch TC100, a groundbreaking early detection test for testicular cancer in the UK, offering unparalleled accuracy for improved patient care...
Optima Health Plc has announced its acquisition of Cognate Health Limited for up to €9 million, expanding its footprint in the Irish occupational health sector...
Bishop David Walker's prostate cancer diagnosis highlights the importance of early detection and proactive healthcare, urging men to get tested before symptoms arise...
hVIVO plc reports impressive audited results for 2024, showcasing a revenue increase and strong EBITDA growth in the human challenge clinical trial sector...
Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...
Under CEO Adam Binns, One Health Group has revolutionized healthcare through innovation, talent development, and strategic growth, achieving remarkable financial success...
AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...
AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...
GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition...
Haleon plc has released its Annual Report for 2024, detailing vital financial information and upcoming AGM plans. Discover key insights for investors now...
AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...
The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...
Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025...
Convatec Group Plc reports robust FY24 results with double-digit growth in EPS and cash flow, driven by strategic execution and expanded product offerings...
Search

Funds

Financial Services

Discover how FluCamp pioneers clinical trials, bridging lab discoveries and revolutionary treatments, ensuring safety and efficacy in modern medicine...
Cizzle Biotechnology Holdings plc has launched a new corporate website, enhancing access to vital information about its early cancer tests and growth strategy...
Professor Sir Chris Evans, Founder and Chief Scientific Officer of EDX Medical, explains how this revolutionary blood test could reshape early diagnosis and monitoring..
Convatec Group Plc celebrates the CMS's postponement of LCDs for diabetic foot ulcers, ensuring continued access to their trusted InnovaMatrix® for Medicare patients...
Poolbeg Pharma is innovating in oncology with POLB 001, a promising p38 MAP kinase inhibitor targeting Cytokine Release Syndrome, a critical complication in cancer therapies...
One Health Group is set to transform orthopaedic care in the North of England with its first surgical hub, enhancing patient access to essential NHS services...
EDX Medical Group is set to launch TC100, a groundbreaking early detection test for testicular cancer in the UK, offering unparalleled accuracy for improved patient care...
Optima Health Plc has announced its acquisition of Cognate Health Limited for up to €9 million, expanding its footprint in the Irish occupational health sector...
Bishop David Walker's prostate cancer diagnosis highlights the importance of early detection and proactive healthcare, urging men to get tested before symptoms arise...
hVIVO plc reports impressive audited results for 2024, showcasing a revenue increase and strong EBITDA growth in the human challenge clinical trial sector...
Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...
Under CEO Adam Binns, One Health Group has revolutionized healthcare through innovation, talent development, and strategic growth, achieving remarkable financial success...
AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...
AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...
GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition...
Haleon plc has released its Annual Report for 2024, detailing vital financial information and upcoming AGM plans. Discover key insights for investors now...
AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...
The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...
Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025...
Convatec Group Plc reports robust FY24 results with double-digit growth in EPS and cash flow, driven by strategic execution and expanded product offerings...
Search

Funds

Health

FTSE 100

Funds